Nav: Home

Genetic mutations predict patient response to immunotherapy

June 08, 2017

Results of a new clinical study establish particular genetic defects in tumors as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade. Until recently, PD-1 blockade therapies have only been approved for a select few classes of cancers, such as colon cancer. Because clinical tests for the particular indicator defects identified here are widely available, these results could establish a new standard of care to test for them in tumors, the authors say, helping to more efficiently identify those patients who might benefit from immunotherapy. In an 86-participant clinical trial across 12 different types of cancer, Dung Le et al. found the immunotherapy pembrolizumab (an anti-PD-1 antibody) was actually effective against multiple forms of cancer. The drug controlled disease for 66 patients, and tumors completely disappeared in 18 people. The responding tumors all had defects in a genome maintenance pathway called mismatch repair (MMR). PD-1 blockade therapies can unleash the immune system against aberrant proteins on the surface of malignant cells called neoantigens, which accumulate because some cancers have inherently unstable genomes. The researchers characterized neoantigens in biopsy sample responses from three responding patients to confirm that MMR-deficient cancers contained immune cells that can be let loose against tumors using PD-1 blockade. The scientists determined that immunotherapy might be useful for as many as 60,000 MMR-mutant cancer cases every year in the United States, based on analysis of genome sequencing data from 12,019 cancers representing 32 distinct tumor types. Though the trial is still ongoing, 11 patients were able to stop taking the therapy since beginning; they have remained disease-free with no evidence of recurrence for an average of 8.3 months.
-end-


American Association for the Advancement of Science

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...